Biologics News
How Proactive Specialty Pharmacy Care Helps Prevent Medication Waste
Read about how Biologics by McKesson uses proactive pharmacy care and personalized support to help patients stay on therapies, reduce costs and improve outcomes.
ZYCUBO® (copper histidinate), First FDA-Approved Treatment for Patients with Menkes Disease, Exclusively Available at Biologics by McKesson in the United States
Cary, N.C. , Jan. 13, 2026 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease
Biologics by McKesson’s Pharmacy Elite™ Selected as Hub for Rigel Pharmaceuticals’ Tavalisse®, Gavreto® and Rezlidhia®
Cary, N.C. , Jan. 2, 2026 – Biologics by McKesson’s Pharmacy Elite™, has been awarded the Rigel Pharmaceuticals Hub contract
AQVESME® (mitapivat), FDA-Approved for Adults with Thalassemia, Exclusively Available at Biologics by McKesson
Cary, N.C. , Dec. 29, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene,
The Future of Oncology is Personal, and It’s Already Here
Learn how McKesson connects biopharma, providers and patients to deliver precision oncology at scale through integrated logistics, specialty pharmacy and high‑touch support.
KOMZIFTI® (ziftomenib), FDA-Approved for Treatment of Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia, Available at Biologics by McKesson
Cary, N.C. , Nov. 13, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease